Immunocellular ($IMUC) - Moving forward in Brain Cancer

IMUC is developing ICT-107, an autologous, dendritic cell-based vaccine (like Dendrion's Provenge) that works by activating a patient's immune system against specific tumor-associated antigens. This is accomplished by extracting dendritic cells from a patient, loading them with the antigens, and reintroducing them to the patient's body to trigger an immune response. It is still early days, but IMUC is targeting glioblastoma multiforme (aggressive brain cancer) with this product. Data from Phase 1 trials has been encouraging and the company is embarking on a P2 program. The company is also developing ICT-140: Dendritic cell-based vaccine for the treatment of ovarian cancer. This product will target multiple antigens present on cancer stem cells and daughter cells. Interesting because we have discussed Prima BioMed's dendritic approach in ovarian cancer too.

This is not new news, but its worthy of mention, according to a blurb we saw in Bio Century, IMUC announced in early December the company’s plans to raise capital in a follow-on offering with a goal to raise up to $13.8 million in cash (10 million at $1.40) with 1:1 share – warrant coverage.